Pfizer share news, announcements and annual reports
NSE: PFIZERBSE: 500680Pharmaceuticals & BiotechnologySmall Cap
Pfizer Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 1966 on BSE, Apr 1999 on NSE
Last close ₹3,638.70down ₹49.10 (1.33%)BSE ₹3,637.90
Share price at the NSE close on 2 Nov 2026. Previous close ₹3,687.80.
2 Nov: open ₹3,687.80, high ₹3,718.20, low ₹3,613.60
52-week range of traded prices to 2 Nov 2026
₹3,589.00Low, 23 Oct 2026₹5,339.00High, 13 Nov 2025
- Next results date: the board meets on 3 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹16,646 Cr327th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 22.64
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 3.96
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 2.06%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 17.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 21.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 55,74259.3% delivered
Pfizer share news and announcements
658 announcements, routine notices left out, newest first. Page 10 of 14.
Jun 2015
5 Jun · Change in Managing Director
May 2015
20 May · Code of Conduct under SEBI(PIT) Reg., 2015
5 May · Dividend
Board of Directors at its meeting held on May 05, 2015 has recommended a dividend of Rs.12.50/- per Equity share of Rs.10/- each (125%) for the financial year ended March 31, 2015. The said dividend, if declared at the ensuing Annual General Meeting of the Company, shall be paid on July 28, 2015.
Apr 2015
Feb 2015
Jan 2015
28 Jan · Board meeting
Inter alia, to consider and take on record the Unaudited Financial Results of the Company for the third quarter and nine months ended December 31, 2014.
Dec 2014
Nov 2014
Oct 2014
31 Oct · Updates
Hon'ble High Court of Judicature at Bombay on October 31, 2014 considered and approved the amalgamation of Wyeth Limited with the Company, in terms of the scheme of amalgamation between Wyeth Limited, the Company and their respective shareholders and creditors under the provisions of Sections 391 to 394 of the Companies Act, 1956.21 Oct · Board meeting
Inter alia, to consider and take on record the Unaudited Financial Results of the Company for the second quarter and six months ended September 30, 2014. Further Trading Window for trading in the Equity shares of the Company will be closed from October 22, 2014 to November 7, 2014, both days inclusive.20 Oct · Meeting
Register of Members and Share Transfer Books of the Company will remain closed from October 31, 2014 to November 10, 2014 for the purpose of Annual General Meeting of the Company to be held on November 10, 2014.14 Oct · Legal
Exchange had sought clarification from Pfizer Limited regarding news item captioned "Pfizer wins patent for Voriconazole". The Company has clarified that "The news article appeared to be attributable to our parent Company Pfizer Inc., USA or its affiliates and not in respect to our Company, Pflzer Ltd.If and when we make any announcement regarding any material activity for our business, we will ensure that we continue to follow the mandated procedures of informing stock exchanges in a timely manner, so as to ensure uniform and simultaneously disclosure to all investors".14 Oct · Legal
Exchange has sought clarification from Pfizer Limited with respect to recent news item captioned "Pfizer wins patent for Voriconazole". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement.The response from the Company is awaited.
Aug 2014
27 Aug · Meeting
Pursuant to Section 96 of the Companies Act, 2013 the Company had made an application to the Registrar of Companies, Maharashtra, Mumbai ('RoC') seeking an extension of time for holding its Annual General Meeting (AGM) for the financial year ended March 31, 2014. Further, the Company has informed that the RoC has granted the Company time up to December 30, 2014 to hold its AGM. The date of the AGM will be intimated in due course.
Jul 2014
24 Jul · Results
14 Jul · Board meeting
Inter alia, to consider and take on record the Unaudited Financial Results of the Company for the 1st quarter ended June 30, 2014. Please be informed that the Trading Window for trading in the Equity shares of the Company will be closed from July 15, 2014 to July 25, 2014, both days inclusive.
May 2014
23 May · Court Convened Meeting Updates
5 May · Board meeting
Company paid an interim dividend of Rs. 360/- per share of Rs. 10/- each (3600%) aggregating to Rs. 1,07,429 Lakhs. The Board of Directors Company have not recommended any further Dividend for the financial year ended March 31, 2014.
Apr 2014
29 Apr · News Verification
News Verification : The media had reports that "Pfizer in talks to buy Wockhardt's India assets.". The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Pfizer Limited has vide its letter inter-alia stated,"The news item is speculative in nature and was not authorized by, or attributable to any statements made by or on behalf of, Pfizer Limited. We confirm that our Company, Pfizer Limited does not have any such proposal as contemplated in the news article referred in your captioned letter."25 Apr · Meeting